Loading...

Xenon Pharmaceuticals

DB:XP0
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
XP0
DB
$244M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
XP0 Share Price and Events
7 Day Returns
2.3%
DB:XP0
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
109.8%
DB:XP0
-7.4%
DE Biotechs
-5.6%
DE Market
XP0 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Xenon Pharmaceuticals (XP0) 2.3% -5% 21.1% 109.8% 29.8% -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • XP0 outperformed the Biotechs industry which returned -7.4% over the past year.
  • XP0 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
XP0
Industry
5yr Volatility vs Market

XP0 Value

 Is Xenon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Xenon Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €8.015.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Xenon Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Xenon Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:XP0 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.63
NasdaqGM:XENE Share Price ** NasdaqGM (2019-04-24) in USD $9.47
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Xenon Pharmaceuticals.

DB:XP0 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XENE Share Price ÷ EPS (both in USD)

= 9.47 ÷ -1.63

-5.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xenon Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Xenon Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Xenon Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:XP0 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
38%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Xenon Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Xenon Pharmaceuticals's assets?
Raw Data
DB:XP0 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.71
NasdaqGM:XENE Share Price * NasdaqGM (2019-04-24) in USD $9.47
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:XP0 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XENE Share Price ÷ Book Value per Share (both in USD)

= 9.47 ÷ 3.71

2.55x

* Primary Listing of Xenon Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Xenon Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Xenon Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Xenon Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

XP0 Future Performance

 How is Xenon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Xenon Pharmaceuticals expected to grow at an attractive rate?
  • Xenon Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Xenon Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Xenon Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:XP0 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:XP0 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 38%
DB:XP0 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 58.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:XP0 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:XP0 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 146 -83 81 1
2022-12-31 77 -102 -16 2
2021-12-31 54 -80 -18 2
2020-12-31 6 -38 -44 2
2019-12-31 0 -40 -41 3
DB:XP0 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -35 -32
2018-09-30 0 -34 -31
2018-06-30 0 -29 -26
2018-03-31 0 -30 -27
2017-12-31 0 -29 -31
2017-09-30 1 -27 -29
2017-06-30 1 -22 -29
2017-03-31 1 -21 -27
2016-12-31 2 -20 -23
2016-09-30 5 -20 -21
2016-06-30 9 -21 -17
2016-03-31 12 -18 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Xenon Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Xenon Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:XP0 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Xenon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XP0 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.78 2.78 2.78 1.00
2022-12-31 0.16 2.91 -2.59 2.00
2021-12-31 -0.28 1.93 -2.48 2.00
2020-12-31 -1.62 -1.55 -1.68 2.00
2019-12-31 -1.62 -1.50 -1.74 2.00
DB:XP0 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.63
2018-09-30 -1.79
2018-06-30 -1.55
2018-03-31 -1.50
2017-12-31 -1.71
2017-09-30 -1.59
2017-06-30 -1.66
2017-03-31 -1.66
2016-12-31 -1.48
2016-09-30 -1.43
2016-06-30 -1.19
2016-03-31 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Xenon Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Xenon Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Xenon Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

XP0 Past Performance

  How has Xenon Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Xenon Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Xenon Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Xenon Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Xenon Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Xenon Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Xenon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:XP0 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -31.62 8.38
2018-09-30 0.02 -31.50 8.02 25.45
2018-06-30 0.28 -26.37 7.83 24.55
2018-03-31 0.30 -26.91 7.45 25.20
2017-12-31 0.31 -30.70 7.31
2017-09-30 0.67 -28.64 7.09 4.40
2017-06-30 0.82 -28.62 7.12 21.77
2017-03-31 1.22 -27.25 7.00 20.47
2016-12-31 1.80 -23.00 6.79 18.71
2016-09-30 4.65 -20.93 6.92 18.01
2016-06-30 8.54 -17.04 6.46 15.70
2016-03-31 12.17 -9.86 4.96 13.90
2015-12-31 15.58 -15.75 9.79 12.39
2015-09-30 17.23 -2.39 9.61 11.11
2015-06-30 26.13 5.03 9.60 9.40
2015-03-31 27.38 3.86 10.78 7.37
2014-12-31 28.37 13.02 5.50 5.87
2014-09-30 29.08 6.11 4.93 4.39
2014-06-30 26.67 3.83 5.30 4.03
2014-03-31 26.86 3.83 5.36 5.12
2013-12-31 27.36 3.83 5.34 6.09
2013-09-30 24.82 -0.11 6.24 5.93
2013-06-30 17.08 -2.85 6.27 5.60
2013-03-31 15.70 -3.58 6.64 4.37
2012-12-31 14.31 -4.30 7.01 3.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Xenon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Xenon Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Xenon Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Xenon Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Xenon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

XP0 Health

 How is Xenon Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Xenon Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Xenon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Xenon Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Xenon Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Xenon Pharmaceuticals Company Filings, last reported 3 months ago.

DB:XP0 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 103.30 15.01 119.31
2018-09-30 111.16 14.89 127.13
2018-06-30 50.62 11.72 63.27
2018-03-31 28.50 6.88 35.08
2017-12-31 35.93 6.80 43.67
2017-09-30 43.30 0.00 43.77
2017-06-30 50.45 0.00 51.70
2017-03-31 57.20 0.00 58.03
2016-12-31 63.90 0.00 64.15
2016-09-30 69.31 0.00 69.49
2016-06-30 52.66 0.00 50.74
2016-03-31 58.16 0.00 56.06
2015-12-31 61.03 0.00 58.65
2015-09-30 64.46 0.00 65.47
2015-06-30 64.35 0.00 73.70
2015-03-31 62.67 0.00 75.38
2014-12-31 72.78 0.00 84.04
2014-09-30 34.98 0.00 47.94
2014-06-30 27.11 0.00 44.71
2014-03-31 24.12 0.00 49.28
2013-12-31 24.12 0.00 49.28
2013-09-30
2013-06-30 15.29 0.00 49.81
2013-03-31 15.29 0.00 49.81
2012-12-31 12.62 1.67 60.16
  • Xenon Pharmaceuticals's level of debt (14.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 14.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Xenon Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.
  • Xenon Pharmaceuticals has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 23.6% each year.
X
Financial health checks
We assess Xenon Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Xenon Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

XP0 Dividends

 What is Xenon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Xenon Pharmaceuticals dividends.
If you bought €2,000 of Xenon Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Xenon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Xenon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:XP0 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:XP0 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Xenon Pharmaceuticals has not reported any payouts.
  • Unable to verify if Xenon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Xenon Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Xenon Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Xenon Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Xenon Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Xenon Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

XP0 Management

 What is the CEO of Xenon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Simon Pimstone
COMPENSATION $1,469,198
AGE 50
TENURE AS CEO 16.3 years
CEO Bio

Dr. Simon N. Pimstone, M.B. ChB., Ph.D., FRCPC, M.D, is a Scientific Co-Founder of Xenon Pharmaceuticals Inc. in 1996 and has been its Chief Executive Officer since January 2003. He had served as President of Xenon Pharmaceuticals Inc. since January 2003 to March 2018 Dr. Pimstone served as the Chief Operating Officer since October 2001 and Vice President, Clinical and Medical Affairs since March 1999 for Xenon Pharmaceuticals Inc. He has served as a consultant physician at the St. Paul’s Hospital Lipid Clinic, Vancouver, BC and an investigator in the Clinical Trials Unit of the Lipid Clinic. He serves as the Chairman of the Providence Healthcare Research Trust. Dr. Pimstone is the author of numerous peer-reviewed publications and book chapters and is also a regular guest speaker at scientific meetings. He served as Clinical Director of the Healthy Heart Society British Columbia Lipid Clinic Outreach Program, a network of lipid clinics serving approximately 4 million people. He is an internal medicine specialist with an interest and expertise in cardiovascular disease. Dr. Pimstone serves as the Chairman of Eupraxia Pharmaceuticals Inc. Dr. Pimstone serves as a Director of Indel Therapeutics Inc. He has been a Director at Xenon Pharmaceuticals Inc. since November 1996 and serves as a Director of BC Biotech. Dr. Pimstone was named in the Globe & Mail’s Canadian Top 40 Under 40 Award. He has extensive training as a clinical and research fellow with the Department of Medical Genetics at the University of British Columbia and obtained his PhD through the University of Amsterdam in cardiovascular genetics. He received his MD from the University of Cape Town where he practiced medicine.

CEO Compensation
  • Simon's compensation has increased whilst company is loss making.
  • Simon's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Xenon Pharmaceuticals management team in years:

5.2
Average Tenure
56
Average Age
  • The average tenure for the Xenon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Simon Pimstone

TITLE
CEO & Director
COMPENSATION
$1M
AGE
50
TENURE
16.3 yrs

Ian Mortimer

TITLE
President
COMPENSATION
$945K
AGE
42
TENURE
1.1 yrs

Robin Sherrington

TITLE
Executive Vice President of Business & Corporate Development
COMPENSATION
$553K
AGE
57
TENURE
7.2 yrs

James Empfield

TITLE
Senior Vice President of Drug Discovery of Xenon Pharmaceuticals USA Inc
COMPENSATION
$545K
AGE
57
TENURE
3.2 yrs

Charles Cohen

TITLE
Vice President of Biology
COMPENSATION
$766K
AGE
70
TENURE
11.3 yrs

Ernesto Aycardi-Fonseca

TITLE
Chief Medical Officer of Xenon Pharmaceuticals USA Inc.
AGE
55
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Xenon Pharmaceuticals board of directors in years:

15.5
Average Tenure
62
Average Age
  • The average tenure for the Xenon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Tarnow

TITLE
Chairman
COMPENSATION
$89K
AGE
74
TENURE
19.9 yrs

Simon Pimstone

TITLE
CEO & Director
COMPENSATION
$1M
AGE
50
TENURE
22.4 yrs

Frank Holler

TITLE
Independent Director
COMPENSATION
$62K
AGE
61
TENURE
20.1 yrs

Gary Patou

TITLE
Independent Director
COMPENSATION
$60K
AGE
59
TENURE
15.3 yrs

Mohammad Azab

TITLE
Independent Director
COMPENSATION
$57K
AGE
62
TENURE
15.5 yrs

Michael Hayden

TITLE
Independent Director
COMPENSATION
$46K
AGE
67
TENURE
22.4 yrs

Richard Scheller

TITLE
Independent Director
COMPENSATION
$52K
AGE
65
TENURE
4.1 yrs

Steve Gannon

TITLE
Independent Director
COMPENSATION
$55K
AGE
57
TENURE
3.9 yrs

Graham Svoronos

TITLE
Independent Director
COMPENSATION
$51K
AGE
65
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Xenon Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Xenon Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

XP0 News

Simply Wall St News

XP0 Company Info

Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy. The company’s product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in phase I clinical trials. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Details
Name: Xenon Pharmaceuticals Inc.
XP0
Exchange: DB
Founded: 1996
$217,892,921
25,751,266
Website: http://www.xenon-pharma.com
Address: Xenon Pharmaceuticals Inc.
200 – 3650 Gilmore Way,
Burnaby,
British Columbia, V5G 4W8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XENE Common Shares Nasdaq Global Market US USD 05. Nov 2014
DB XP0 Common Shares Deutsche Boerse AG DE EUR 05. Nov 2014
Number of employees
Current staff
Staff numbers
91
Xenon Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 22:48
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.